important to remember that "lower levels of COVID in Africa" =/= actual lower prevalence of SARS-COV-2 infections
As summarised in a recent systematic review:
"Precisely estimating COVID-19 cumulative incidence in Africa remains problematic due to challenges in contact tracing, routine surveillance systems and laboratory testing capacities and strategies in many countries. Furthermore, Africa is a large, complex and heterogeneous continent with a range of different economies, countries impacted by humanitarian crises, vulnerable population groups and unique public health challenges."
I've copied a summary of the paper below:
gh.bmj.com/content/7/8/e008793
WHAT IS ALREADY KNOWN ON THIS TOPIC
There is limited published evidence on the seroprevalence of SARS-CoV-2 in Africa, including one previous systematic review and meta-analysis in the general population for the continent and global systematic reviews that under-represent studies in Africa due to sparse data.
Recently, in part via WHO’s Unity studies, the quantity and quality of available seroprevalence data has increased, providing the opportunity to understand the true extent of exposure to SARS-CoV-2 in Africa, disaggregated by demographic groups, place (eg, subregion, country) and time.
WHAT THIS STUDY ADDS
Our results indicate a high seroprevalence in Africa (65.1%) in July–September 2021, which had increased from 3.0% in April–June 2020, and large, persistent under-ascertainment of infection based on confirmed case-based data.
Our results also indicate considerable heterogeneity in seroprevalence within countries and between countries and African subregions.
HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
High, heterogeneous seroprevalence in Africa highlights the need for targeted serosurveillance, public health and social measures and vaccination strategies tailored to the local context, particularly to address geographic and demographic vulnerabilities.